Biosimilar Education: Who know what about biologic generics and how are they making decisions

BIOSIMILAR EDUCATION who knows what about biologic generics and how are they making decisions www.ISRreports.com WHAT ARE BIOSIMILARS? biosimilars (bīo simələrs) noun - a term used to describe officially approved subsequent (or "generic") versions of innovative biopharmaceutical products made by a different manufacturer following patent and exclusivity expiry of the innovator product. THE U.S.CONSUMER 38% 46% don't know have never if their main heard of medication is chemical or biologic. biologic medicines. So how do they make decisions regarding medication? THE DECISION-MAKERS DOCTORS PHARMACISTS 82% 69% of patients say of patients at least occasionally consult a their doctor decides the brand of their pharmacist on which drug to take. medication. AND Most patients will stay on a more expensive brand name drug if their doctor recommends it. THE PROBLEM 54%) 78% of pharmacists of primary care physicians can't define 'biosimilars' THE LAW FDA guidance around biosimilars is currently in draft form. State legislatures have seen an influx of bills on biosimilars, but the details vary. PHYSICIAN NOTIFICATION In all states, doctors can block a generic switching at the pharmacy level with a "dispense as written" instruction, but some states put additional responsibility on the pharmacist to notify the prescribing practitioner if a biosimilar switch is made. The timelines for notification, shown below, vary from state to state. | 24 hours 3 days 12 days I No physician notification required 1 5 days THE EFFECTS OF PATIENT EDUCATION ISR measured the relative importance of attributes for driving drug choices. Half the respondents were given a definition of a biologic, and half were not. Here's how that knowledge affected the relative importance of a doctor recommendation. NOT GIVEN DEFINITION vs. GIVEN BIOLOGIC DEFINITION 62% 53% Find out which attributes became more important when patients were given the biologic definition in ISR's Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines report. IMPLICATIONS FOR PHARMA Patients are relatively unaware of biosimilars, and ISR's portfolio of biosimilar research suggests that healthcare professionals (physicians, pharmacists, oncologists) are also unfamiliar with biosimilars and should not be overlooked as education targets. SOURCES: Industry Standard Research (Biosimilar Primer Series) www.openstates.org DIA Daily ISR reports [email protected] @ISRREPORTS ISRREPORTS.COM